FDA asked again to approve apomorphine pump SPN-830

Supernus Pharmaceuticals has asked the U.S. Food and Drug Administration (FDA) again to approve the apomorphine infusion pump SPN-830 for treating Parkinson’s disease. “We look forward to continuing our effort with the FDA throughout the NDA [new drug application] review process to bring a promising alternative to…